NCT01456585 2018-08-27Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaAbramson Cancer Center at Penn MedicinePhase 1 Completed10 enrolled